Principal Investigator: Dr. Robert Cotes
Criteria: We are looking to recruit patients who meet the following key criteria:
Purpose: This study evaluates the efficacy of 10 mg/day Lu AF35700 on symptoms of schizophrenia in patients with early-in-disease (ED) or late-in-disease (LD) treatment-resistant schizophrenia (TRS). Eligible patients will be randomized at some point in the trial to receive either the investigational medication or treatment with either risperidone or olanzapine at an adequate and tolerable dose established during the study. The study will last for approximately 23 weeks.
Compensation: $85 for each study visit
Contact: Ayesha Khan (Study Coordinator)
Phone: 404-616-0853
Email: akhan31@emory.edu
Website link: https://clinicaltrials.gov/ct2/show/NCT03230864